New imaging agent could revolutionize cancer detection
NCT ID NCT07459192
First seen Mar 19, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This study will test a new imaging agent called 68Ga-DOTA-BLP in 50 adults with confirmed cancer. The goal is to see if a PET scan using this agent can noninvasively detect PD-L1, a protein that helps tumors hide from the immune system. This could help doctors better diagnose cancer and decide which patients might benefit from immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANSER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Daping Hospital, Army Medical University
Chongqing, Chognqing, 400010, China
Conditions
Explore the condition pages connected to this study.